联系客服

600479 沪市 千金药业


首页 公告 600479:千金药业2021年半年度主要经营数据公告

600479:千金药业2021年半年度主要经营数据公告

公告日期:2021-08-27

600479:千金药业2021年半年度主要经营数据公告 PDF查看PDF原文

  证券代码:600479      证券简称:千金药业        公告编号:2021-026
                    株洲千金药业股份有限公司

                  2021 年半年度主要经营数据公告

  本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。

      根据《上市公司行业信息披露指引第七号——医药制造》、《关于做好上市
  公司 2021 年半年度报告披露工作的通知》 的要求,公司现将 2021 年半年度主
  要经营数据披露如下:
一、报告期内公司主营业务分行业、分产品经营情况

                                                单位:元 币种:人民币
                          主营业务分行业情况

                                                营业  营业

                                          毛利  收入  成本  毛利率比
  分行业      营业收入      营业成本  率(%) 比上  比上  上年增减
                                                年增  年增    (%)
                                                减(%) 减(%)

  药品生产    771,235,628.54  205,228,486.75  73.39  11.35  4.73  增加 1.68
                                                                        个百分点

中药材及饮片  23,720,424.51    19,688,630.32  17.00  10.86  2.86  增加 6.46
    生产                                                                个百分点

药品批发零售  847,640,056.28  708,342,455.86  16.43  -2.85  -5.19  增加 2.07
                                                                        个百分点

    其他      134,451,258.91  54,946,661.95  59.13  33.00  41.89  减少 2.56
                                                                        个百分点

  合并抵销    -55,967,341.87  -56,630,469.55

    合计      1,721,080,026.37  931,575,765.33  45.87  3.48  -4.54  增加 4.55
                                                                        个百分点

                          主营业务分产品情况


                                              营业收  营业成  毛利率
 分产品      营业收入      营业成本    毛利  入比上  本比上  比上年
                                        率(%) 年增减  年增减  增减(%)
                                                (%)  (%)

                                                                          增加

 中药生产    444,818,386.73  116,243,198.41  73.87  16.32    -0.21    4.33 个
                                                                          百分点

                                                                          减少

 西药生产    326,417,241.81  88,985,288.34  72.74    5.22    11.97    1.64 个
                                                                          百分点

中药材及饮                                                                增加

  片生产    23,720,424.51    19,688,630.32  17.00  10.86    2.86    6.46 个
                                                                          百分点

药品批发零                                                                增加

    售      847,640,056.28  708,342,455.86  16.43  -2.85    -5.19    2.07 个
                                                                          百分点

                                                                          增加

  娱乐      20,150,798.94    8,154,590.95  59.53  1,049.74  1,010.64  1.42 个
                                                                          百分点

                                                                          减少

 卫生用品    110,786,164.03  44,749,032.41  59.61  14.90    25.29    3.35 个
                                                                          百分点

                                                                          增加

  其他      3,514,295.94    2,043,038.59  41.86  20.34    -10.17  19.74 个
                                                                          百分点

 合并抵消    -55,967,341.87  -56,630,469.55

                                                                          增加

  合计    1,721,080,026.37  931,575,765.33  45.87    3.48    -4.54    4.55 个
                                                                          百分点

    报告期内,主营业务收入增长 3.48%,主营业务成本下降 4.54%,毛利率增加
4.55 个百分点。

  中药生产板块毛利率增加 4.33 个百分点,主要是本期产量大幅增长导致成本率下降所致。

  药品批发零售板块毛利率增加 2.07 个百分点,主要是医药批发企业销售结构变化所致。

    娱乐板块上期因受疫情影响,本期营业收入同比增长 1049.74%。

二、报告期内公司主营业务分地区经营情况

                                              单位:元 币种:人民币

                      主营业务分地区情况

    地区      2021 年 1-6 月累计主营业务收入  营业收入比上年增减(%)

    华东              227,312,926.71                    11.93

    华南              113,856,636.97                    31.82

    华北              85,670,749.40                    11.97

    华中            1,026,323,091.21                  10.70

    东北              41,691,779.10                    22.86

    西南              167,398,403.05                  -39.41

    西北              58,826,439.93                    -1.75

    合计              1,721,080,026.37                    3.48

  报告期内,华南地区增长 31.82%,西南地区下降 39.41%,主要是因药品批发企业千金医药销售变动所致。

  本公告之经营数据未经审计,提醒投资者审慎使用上述数据。

  特此公告。

                                              株洲千金药业股份有限公司
                                                        董事会

                                                    2021 年 8 月 27 日

[点击查看PDF原文]